OliX Pharmaceuticals Inc.

In News

OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications - Business Wire

Business Wire - Feb 10, 2025

OliX secures ₩115 billion investment through convertible preferred shares - koreabiomed.com

koreabiomed.com - Aug 20, 2025

Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH - Pharmaceutical Technology

Pharmaceutical Technology - Feb 11, 2025

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH - Fierce Biotech

Fierce Biotech - Feb 10, 2025

APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses - BioWorld MedTech

BioWorld MedTech - Feb 18, 2025

Driving drug development through next-generation oligonucleotide technology - Nature

Nature - Sep 02, 2020

OliX Registers European Substance Patent for Hair Loss Treatment ‘OLX104C’ - Businesskorea

Businesskorea - Jul 30, 2025

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate - Yahoo Finance

Yahoo Finance - Feb 10, 2021

Eli Lilly acquires OliX Pharmaceuticals' OLX702A for metabolic disease treatment - CHOSUNBIZ - Chosunbiz

Chosunbiz - Feb 10, 2025

OliX Pharmaceuticals Announces Positive Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar Treatment - BioSpace

BioSpace - Apr 28, 2023

Olix wins $630M deal from Eli Lilly for phase I MASH asset - BioWorld MedTech

BioWorld MedTech - Feb 10, 2025

OliX strikes $630 million deal with Lilly for obesity and liver disease drug - koreabiomed.com

koreabiomed.com - Feb 10, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment